The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

To evaluate the virological efficacy and safety at week 48 of 2 regimens atazanavir/ritonavir (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in combination with a fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-naïve subjects with CD4 counts below 200 µL

• Evaluate the viral load of HIV-1 at week 0, week 4 and week 48 on the seminal fluid (substudy)

Immunologic response [ Time Frame: W-4,W2,W4,W12,W24 and W48 ]

• Evaluate the immunologic response by the CD4 mesearement at W-4,W2,W4,W12,W24 and W48

Differenciation and activation of lymphocytes [ Time Frame: W0,W2,W4,W12,W24 and W48 ]

At the end of the study, in a central lab, we will measure some inflammation and activation markers (CD69, HLA-DR, CD38, annexine V, IL-6, CD14s, IL-7 plasma) of lymphocytes CD4 and CD8(with the plasmatheque collected during the study)

Pharmacokinetics evaluation of the drugs in plasma [ Time Frame: W4,W24 and W48 ]

The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal

Drug: ATAZANAVIR

The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules

Other Name: REYATAZ

Experimental: DARUNAVIR

The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal

Drug: DARUNAVIR

The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria

Male or female, aged > 18 years of age

HIV-1 infection determined by a positive ELISA and confirmed by Western blot

Plasma HIV-RNA > 1 000 c/mL

CD4+T cell count < =200 cells/mm3 at the time of screening, or < =250 cells/mm3 if the CD4 count was <200 cells/mm3 12 weeks before screening

Women of childbearing potential must agree to use an effective method of barrier contraception or have documented sterility

Subjects must have medical insurance throught the Securite Sociale

Ability to understand and provide written informed consent

Exclusion Criteria

Acute opportunistic infection within the past two weeks

HIV-2 infection

Pregnant woman

Any subject with drug resistance mutations at screening

Any subject with a grade 3 or greater clinical or laboratory adverse event at screening

Any subject who has received antiretoviral therapy except for prevention of mother to child transmission and patients who has received post exposure prophylaxis for a a month or less